14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ZURA vs CAMP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ZURA carries a Unified Composite Score of 46.3/100 (HOLD) at $1.00 (N/M Forward P/E, 0.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin).
Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 43.9/100 HOLD), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY).
Technical & Structure Timing Caution: ZURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZURA vs CAMP. Trailing 12-month operating profitability (ZURA 0.0% vs CAMP -991.8%) and valuation multiples (ZURA N/M vs CAMP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $238.5M market capitalization and -991.8% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ZURA vs CAMP Key Questions & Quantitative Answers
As of Nov 17, 2026, CAMP4 Therapeutics Corporation (CAMP) is the stronger overall head-to-head candidate over Zura Bio Limited Class A (ZURA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). ZURA carries a Unified Composite Score of 46.3/100 (HOLD) at $1.00 (N/M Forward P/E, 0.0% operating margin), whereas CAMP carries 43.9/100 (HOLD) at $4.00 (N/M Forward P/E, -991.8% operating margin). Composite vs. Pillar Nuance: While ZURA currently prints a higher short-term Unified Composite Score (46.3/100 HOLD vs. CAMP 43.9/100 HOLD), CAMP captures the overall institutional head-to-head verdict (4–3 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-991.8% vs. 0.0% operating margin) and revenue trajectory (+138.9% vs. +0.0% YoY). Technical & Structure Timing Caution: ZURA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 24.8); meanwhile CAMP trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 51.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CAMP leads the Growth & Scale pillar: ZURA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAMP at +138.9% YoY revenue growth and +0.0% YoY earnings growth on $5.3M TTM revenue (N/A gross margin, -991.8% operating margin). On trailing 12-month operating scale, ZURA generates N/A in USD-normalized revenue versus $5.3M for CAMP. In operating R&D and SG&A reinvestment, ZURA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAMP.
CAMP screens cheaper on headline valuation multiples. ZURA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAMP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 26.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZURA (-63.2% ROE) versus CAMP (-146.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ZURA carries 0.2% implied volatility (<1st %ile, Compressed (<25th %ile)), a 1.51x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.56β · 272% Vol realized risk). By comparison, CAMP carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.35β · 94% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.